The DOI matches its Crossref record; 215 of the 215 references it cites were found in a registry or an index.
Activation and activities of the p53 tumour suppressor protein
Open accessAbstract
The p53 tumour suppressor protein inhibits malignant progression by mediating cell cycle arrest, apoptosis or repair following cellular stress. One of the major regulators of p53 function is the MDM2 protein, and multiple forms of cellular stress activate p53 by inhibiting the MDM2-mediated degradation of p53. Mutations in p53, or disruption of the pathways that allow activation of p53, seem to be a general feature of all cancers. Here we review recent advances in our understanding of the pathways that regulate p53 and the pathways that are induced by p53, as well as their implications for cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · cited 1×
“Malignancies that retain the wild-type p53 gene have often acquired other mechanisms to compromise p53 function, and most cancer cells show a defect either in p53 or in the pathway that leads to activation of p53 in response to oncogenic stimuli (Vogelstein et al, 2000).”
BackgroundDeath Receptors: Signaling and Modulation
Ashkenazi, A., & Dixit, V. M. (1998) · Science · doi:10.1126/science.281.5381.1305 · Cited by 5,866
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
Toshiyuki, M., & Reed, J. C. (1995) · Cell · doi:10.1016/0092-8674(95)90412-3 · Cited by 4,063
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 1×
“However, a more comprehensive inhibition of p53 function is achieved by the ability of MDM2 to promote proteasome-mediated degradation of p53 (Haupt et al, 1997; Kubbutat et al, 1997).”
BackgroundSelf-citationMomand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113 · cited 1×
“MDM2 binds to p53 within the amino terminus of p53, (Figure 1) directly blocking the interaction of p53 with transcriptional coactivators (Momand et al, 1992; Wadgaonkar and Collins, 1999) and so inhibiting the ability of p53 to activate transcription of target genes.”
BackgroundKastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047 · cited 2×
“Since the MDM2 gene is a transcriptional target of p53 (Barak et al, 1993), an autoregulatory feedback loop exists in which p53 activates expression of its own negative regulator (Wu et al, 1993).”
Background
Cited by
Live or let die: the cell's response to p53
Vousden, K. H., & Lu, X. (2002) · Nature Reviews Cancer · doi:10.1038/nrc864 · Cited by 3,192
Self-citationUnderstanding protein non-folding
Uversky, V. N., & Dunker, A. K. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2010.01.017 · Cited by 1,186
Haupt, S., Berger, M., Goldberg, Z., & Haupt, Y. (2003) · Journal of Cell Science · doi:10.1242/jcs.00739 · Cited by 1,136
Drug discovery in the ubiquitin–proteasome system
Nalepa, G., Rolfe, M., & Harper, J. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2056 · Cited by 608
Xie, H., Vucetic, S., Iakoucheva, L. M., Oldfield, C. J., Dunker, A. K., Uversky, V. N., & Obradovic, Z. (2007) · Journal of Proteome Research · doi:10.1021/pr060392u · Cited by 560
A decade and a half of protein intrinsic disorder: Biology still waits for physics
Uversky, V. N. (2013) · Protein Science · doi:10.1002/pro.2261 · Cited by 499
Matallanas, D., Romano, D., Yee, K., Meissl, K., Kucerova, L., Piazzolla, D., Baccarini, M., Vass, J. K., Kolch, W., & O'Neill, E. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.08.008 · Cited by 416
Molecular portraits of breast cancer: tumour subtypes as distinct disease entities
Sørlie, T. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.08.021 · Cited by 415
Slug Antagonizes p53-Mediated Apoptosis of Hematopoietic Progenitors by Repressing puma
Wu, W.-S., Heinrichs, S., Xu, D., Garrison, S. P., Zambetti, G. P., Adams, J. M., & Look, A. T. (2005) · Cell · doi:10.1016/j.cell.2005.09.029 · Cited by 398
p53 and DNA damage-inducible expression of the xeroderma pigmentosum group C gene
Adimoolam, S., & Ford, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202485699 · Cited by 321
Oncogenes and tumour suppressors take on centrosomes
Fukasawa, K. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2249 · Cited by 312
P53 abnormalities and outcomes in colorectal cancer: a systematic review
Munro, A. J., Lain, S., & Lane, D. P. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602358 · Cited by 289
Anomalous localization in low-dimensional systems with correlated disorder
Izrailev, F. M., Krokhin, A. A., & Makarov, N. M. (2012) · Physics Reports · doi:10.1016/j.physrep.2011.11.002 · Cited by 274
Courtois, S., Verhaegh, G., North, S., Luciani, M.-G., Lassus, P., Hibner, U., Oren, M., & Hainaut, P. (2002) · Oncogene · doi:10.1038/sj.onc.1205874 · Cited by 263
p53, mdm2, EGFR, and msh2 expression in paired initial and recurrent glioblastoma multiforme
Stark, A. M. (2003) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.74.6.779 · Cited by 51
Hengstermann, A., D'silva, M. A., Kuballa, P., Butz, K., Hoppe-Seyler, F., & Scheffner, M. (2005) · Journal of Virology · doi:10.1128/jvi.79.14.9296-9300.2005 · Cited by 38
Miyajima, C., Hayakawa, Y., Inoue, Y., Nagasaka, M., & Hayashi, H. (2022) · Pharmaceuticals · doi:10.3390/ph15081015 · Cited by 17
“Stabilized and activated p53 promotes the expression of target genes, including the cyclin-dependent kinase inhibitor p21 and the apoptosis-inducing factor p53 up-regulated modulator of apoptosis, and negatively regulates tumor proliferation [8,9].”
Background
Metadata
- Authors
- Bálint, É., & Vousden, K. H.
- Venue
- British Journal of Cancer
- Published
- 2001-12
- Volume
- 85
- Issue
- 12
- Pages
- 1813-1823
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W1990431346
- Cited by
- 313
- References
- 215
- FWCI
- 9.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.